嘉必優(688089.SH):DHA產品作為omega-3脂肪酸核心產品,本身具有較大的增長潛力
格隆匯11月21日丨嘉必優(688089.SH)近日投資者關係活動記錄表顯示,DHA產品作為omega-3脂肪酸核心產品,本身具有較大的增長潛力。在嬰配領域,今年以來DHA產品已經體現出了較為明顯的銷量增長。部分魚油大客户也明確了今後兩年由魚油DHA向藻油DHA切換的計劃,對公司來説是一次重要的增長機遇;國際市場方面,也在同步推進DHA進入客户的供應體系;在大健康領域,公司新整合了大健康團隊,期待明年到後年能夠取得業務關鍵節點的突破。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.